Ironwood Pharmaceuticals (NASDAQ:IRWD) was upgraded by BidaskClub from a “strong sell” rating to a “sell” rating in a research report issued on Sunday.

A number of other research firms also recently weighed in on IRWD. Morgan Stanley reaffirmed a “hold” rating on shares of Ironwood Pharmaceuticals in a research note on Monday, December 4th. Bank of America downgraded Ironwood Pharmaceuticals from a “buy” rating to an “underperform” rating and cut their price target for the stock from $20.00 to $15.00 in a research note on Friday, January 5th. Zacks Investment Research downgraded Ironwood Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, January 9th. ValuEngine lowered Ironwood Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, December 29th. Finally, Mizuho lowered Ironwood Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $20.00 to $16.00 in a report on Wednesday, December 6th. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and four have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $17.56.

Shares of Ironwood Pharmaceuticals (IRWD) opened at $13.73 on Friday. Ironwood Pharmaceuticals has a one year low of $12.89 and a one year high of $19.94. The company has a debt-to-equity ratio of -22.31, a quick ratio of 4.86 and a current ratio of 4.87. The firm has a market capitalization of $2,070.00, a PE ratio of -14.30 and a beta of 1.28.

In other news, insider Mark G. Currie sold 60,000 shares of the stock in a transaction dated Wednesday, January 24th. The stock was sold at an average price of $15.45, for a total transaction of $927,000.00. Following the transaction, the insider now owns 835,000 shares of the company’s stock, valued at approximately $12,900,750. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Peter M. Hecht sold 113,405 shares of the stock in a transaction dated Thursday, December 7th. The shares were sold at an average price of $15.12, for a total value of $1,714,683.60. Following the transaction, the chief executive officer now directly owns 4,696,917 shares in the company, valued at approximately $71,017,385.04. The disclosure for this sale can be found here. In the last three months, insiders have sold 174,905 shares of company stock worth $2,666,359. 7.63% of the stock is currently owned by insiders.

Hedge funds and other institutional investors have recently modified their holdings of the company. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Ironwood Pharmaceuticals by 128.6% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,010 shares of the biotechnology company’s stock valued at $135,000 after acquiring an additional 5,069 shares during the last quarter. Gerber Kawasaki Wealth & Investment Management acquired a new stake in Ironwood Pharmaceuticals in the 3rd quarter valued at approximately $170,000. Ameritas Investment Partners Inc. grew its holdings in Ironwood Pharmaceuticals by 5.8% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 11,821 shares of the biotechnology company’s stock valued at $223,000 after buying an additional 648 shares during the last quarter. Hemenway Trust Co LLC acquired a new stake in Ironwood Pharmaceuticals in the 4th quarter valued at approximately $204,000. Finally, Virtu KCG Holdings LLC grew its holdings in Ironwood Pharmaceuticals by 10.3% in the 2nd quarter. Virtu KCG Holdings LLC now owns 15,740 shares of the biotechnology company’s stock valued at $297,000 after buying an additional 1,470 shares during the last quarter.

ILLEGAL ACTIVITY WARNING: This piece of content was reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://theolympiareport.com/2018/02/11/ironwood-pharmaceuticals-irwd-raised-to-sell-at-bidaskclub.html.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases.

Analyst Recommendations for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.